ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 8

Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

July 16, 2024

Ticiana A. Leal, MD, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Afshin Dowlati, MD, Tarita O. Thomas, MD, PhD

Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.

EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

EP. 4: Examining 3-Year Update Data from the CASPIAN Trial

EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC

EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial

Now Viewing

EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

EP. 12: Examining Key Data from DAREON-8

EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

How redefining SCLC as a molecularly heterogeneous malignancy might better inform personalized treatment of its subtypes with unique therapeutic vulnerabilities.
How the mechanism of promoter methylation levels in ctDNA subtypes contribute to “subtype switching” in relapsed SCLC.
1. Potential contribution of subtype switching to treatment resistance (platinum-based chemotherapy)
2. How ‘switching’ to an inflammatory phenotype might improve therapeutic response to immune checkpoint inhibitors vs other SCLC subtypes
3. The variable response of SCLC subtypes to currently available therapies
Briefly discuss significant adverse events in patients with LS-SCLC who receiveIO-based regimens and explore strategies for their mitigation and management.